Search results
Showing 466 to 480 of 662 results for diabetes
This guidance has been updated and replaced by NICE guideline NG3.
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)
Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).
Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)
Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
This evidence summary has been updated and replaced by NICE advice ESNM26.
This evidence summary has been updated and replaced by NICE guideline NG28.
This evidence summary has been updated and replaced by NICE guideline NG28.
This evidence summary has been replaced by NICE technology appraisal guidance 336.
This evidence summary has been updated and replaced by NICE guideline NG28.
This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].
This guidance has been replaced by NICE technology appraisal guidance 63.
This indicator has been updated and replaced by NICE indicator 300 and NICE indicator 301.
This indicator has been updated and replaced by NICE indicator 298 and NICE indicator 299.
This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.